Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
AWARD-6 is a randomized, open, parallel-grouped, multicenter, phase 3, non-inferiority study comparing the safety and efficacy of weekly DUL and daily LIR in patients with uncontrolled T2DM treated with metformin
Hyperoside mediates protection from diabetes kidney disease by regulating ROS-ERK signaling pathway and pyroptosis
IL-6 in inflammation, autoimmunity and cancer
Another study aimed to find a long non-coding RNA (LncRNA) marker associated with ferroptosis in OC and assess how it affects prognosis and clinicopathological features
Sleep and recovery often improve within weeks, while body composition and energy levels noticeably shift within 2 to 3 months
Most data are preclinical
US$ 21.89
US$ 27.63
US$ 26.96
US$ 24.45
US$ 24.91
US$ 25.72
